High-level laser therapy for oral mucositis in children receiving hematopoietic stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study enrolls pediatric patients under 18 who develop WHO grade II or higher oral mucositis during hematopoietic stem cell transplantation. Participants receive high-level laser therapy applied to lesion sites for four consecutive days and are compared with patients receiving basic oral care, with outcomes recorded on the WHO oral mucositis scale. Follow-up visits occur at 7 and 11 days after enrolment to measure changes in severity and healing. Key exclusions include prior photobiomodulation, limited mouth opening, dysplastic oral lesions, and prior head and neck radiotherapy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Children under the age of 18 years undergoing bone marrow transplantation during the phase of oral mucositis.
* Oral mucositis starting from grade II on the WHO scale for OM.
* Willingness to undergo treatment for four consecutive days and to return for evaluation 7 and 11 days after enrolment.

Exclusion Criteria:

* Previous treatment with photobiomodulation for oral mucositis.
* Limited mouth opening less than 2 cm.
* Presence of dysplastic oral lesions.
* Radiotherapy in the head and neck area.
* Vulnerable groups of patients or decision-impaired individuals as prisoners, handicapped and mentally retarded individuals

Where it's running

• Oncology and Bone marrow transplant unit, Children's hospital, Ain Shams University
  Cairo, Cairo Governorate, Egypt Recruiting

Study contacts

• Study coordinator: Asmaa Ayman Gabr, Teaching Assistant
• Email: Asmaagabr@dent.asu.edu.eg
• Phone: +2 01095692889

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Copaiba Mouthwash with Low-Level Laser Therapy to Prevent Mouth Sores After Stem Cell Transplant

  This phase 2 trial tests whether a copaíba-based mouthwash, used four times daily, can help prevent oral mucositis in patients undergoing autologous hematopoietic stem cell transplantation.

  Recruiting Phase 2 Instituto Nacional de Cancer, Brazil · Rio de Janeiro, Rio de Janeiro · NCT07810530

• Chlorophyllin to reduce mouth sores before allogeneic stem cell transplant

  This phase II study tests whether taking chlorophyllin by mouth can lower the chances and severity of mouth ulcers in patients aged 12–65 undergoing radiation-based conditioning before a first allogeneic stem cell transplant.

  Recruiting Phase 2 Tata Memorial Centre · Navi Mumbai, Maharashtra · NCT07709195

• BupiZenge vs Lidocaine for mouth pain from oral mucositis in head and neck cancer

  A phase 3 trial tests whether the BupiZenge lozenge provides better pain relief than lidocaine for mouth sores caused by radiation in head and neck cancer patients.

  Recruiting at 9 sites Phase 3 OncoZenge AB · Copenhagen and 10 other locations · NCT07672236

• Ozone gas plus biomimetic toothpaste and mouthwash to treat cancer therapy mouth sores

  This trial will test whether adding a biomimetic toothpaste and mouthwash to ozone gas therapy helps adults with chemo- or radiotherapy-induced mouth sores heal faster and have less pain.

  Recruiting University of Pavia · Pavia, Lombardy · NCT07491536

• Amimestrocel infusion to prevent severe mouth sores after allogeneic stem cell transplant

  This study will try a single IV infusion of Amimestrocel in adults receiving myeloablative allogeneic stem cell transplants with TBI or melphalan to see if it prevents severe mouth sores.

  Recruiting Phase 2 The First Affiliated Hospital of Soochow University · Suzhu, Jiangsu · NCT07400328

• Low-level laser (photobiomodulation) to prevent mouth sores during radiotherapy for oral cancer

  This study will try low-level laser therapy (photobiomodulation), given five times a week during radiotherapy, to reduce mouth sores in adults treated for oral cancer.

  Recruiting Peter MacCallum Cancer Centre, Australia · Melbourne, Victoria · NCT07387978

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.